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Introduction
The objective of this guideline was to promote evidence-
based, accessible, and comprehensive management of 
hypertension by healthcare professionals in the public 
and private sectors in South Africa. In developing this 
guideline, hypertension and cardiovascular disease (CVD) 
treatment and prevention guidelines were reviewed, as well 
as hypertension trials that reported clinical end-points, and 
involved individuals with important co-morbidities, such as 
diabetes mellitus and chronic kidney disease (CKD). 
Measurement of blood pressure
Blood pressure (BP) is recorded using an approved device. 
The patient should remain in a sitting position for at least 
five minutes. An appropriately sized cuff should be used. 
At the initial consultation, BP should be measured in both 
arms, and if there is any discrepancy, it should be taken 
thereafter in the arm with the higher BP. First, the systolic 
BP should be estimated by palpation, to avoid missing the 
auscultatory gap. 
Self-measurement of BP (SBPM) and ambulatory monitoring 
(ABPM) are recommended for selected target groups and 
circumstances: 
•	 Suspected white-coat (higher readings in the office, 
compared to outside) or masked hypertension (normal 
readings in the office, but higher outside)
•	 To guide antihypertensive medication, especially in high-
risk groups, e.g. the elderly or diabetics
•	 Refractory hypertension
•	 To improve compliance to treatment (SBPM only).
The advantages of SBPM measurement are improved 
assessment of drug effects, detection of causal relationships 
between adverse events and BP response, and improved 
compliance. However, the disadvantages are an increase in 
anxiety and the risk of self-medication. ABPM provides the 
most accurate method to diagnose hypertension, assess 
BP control, and predict outcome. The norms, limitations and 
advantages of office BP, SBPM and ABPM are summarised 
in Table I. 
Cardiovascular disease risk stratification
The rational for assessing CVD risk is that certain risk factors 
confer a great risk of mortality and morbidity. The format of 
the CVD risk assessment is outlined in Table II. Table III lists 
the major risk factors, target-organ damage, and associated 
clinical conditions. Risk factors that are modifiable, e.g. 
smoking, diabetes and dyslipidaemia, should be the target 
of lifestyle intervention and other treatment, as appropriate. 
In addition to controlling hypertension, target-organ damage 
and associated clinical conditions must be managed 
appropriately, and if necessary, referred to a higher level of 
care.
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Abstract
Extensive data from randomised controlled trials have shown the benefit of treating hypertension. The target blood pressure 
(BP) for antihypertensive management is < 140/90 mmHg, and < 130/80 mmHg in patients with end-organ damage, co-
existing risk factors, and co-morbidity. Benefits of management include reduced risk of death, stroke, cardiac failure, 
chronic kidney disease, and coronary heart disease. The correct BP measurement procedure is described, and evaluation 
of cardiovascular risk factors and recommendations for antihypertensive therapy, are stipulated. Lifestyle modification and 
patient education are cornerstones in the management of every patient. Major indications, precautions, and contraindications 
to each recommended antihypertensive drug are listed. Combination therapy should be considered ab initio if the BP is 
≥ 20/10 mmHg above goal. First-line drug therapy for uncomplicated essential hypertension includes low-dose thiazide-
like diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers. The 
guideline was developed by the Southern African Hypertension Society. 
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Routine investigations
Weight, body mass index (BMI), waist circumference, dipstick 
urine, electrolytes, creatinine, and an electrocardiogram 
(ECG) are routine investigations. Apart from measurements 
of overweight and obesity, the tests are performed annually, 
unless abnormal. Abnormal results must be repeated, as 
clinically indicated.
Goals of blood pressure-lowering 
treatment
The goals of BP-lowering treatment vary according to 
number of major risk factors, target-organ damage, 
Table I: Different methods of blood pressure measurement
Clinic Home Ambulatory
Predicts outcome Yes Yes Strongly
Initial diagnosis Yes Yes Yes
Cut-off blood pressure 
levels (in mmHg)
140/90 135/85 135/85  
(mean day)
120/70   
(mean night)
Evaluation of treatment Yes Yes Limited, but valuable
Assess diurnal rhythm No No Yes
Table II: Stratification of risk to quantify prognosis
Blood pressure (mmHg)
Other risk factors 
and disease history
Normal SBP  
120-129 or DBP 80-84













SBP > 180  or
DPB > 110
No other major risk 
factors
Average risk Average risk Low added risk Moderate added risk High added risk
1-2 major risk 
factors
Low added risk Low added risk Moderate added risk Moderate added risk Very high added risk
≥ 3 major risk 
factors, or target-




Moderate added risk High added risk High added risk High added risk Very high added risk
Associated clinical 
conditions
High added  risk Very high added risk Very high added risk Very high added risk Very high added risk
Table III: Major risk factors, target-organ damage and associated clinical conditions  
Major risk factors Target-organ damage Associated clinical conditions
Levels of systolic and diastolic BP
Smoking
Dyslipidaemia 
  Total cholesterol > 5.1 mmol/l, or 
  LDL > 3 mmol/l, or 
  HDL < 1 (men) and < 1.2 mmol/l  
  (women)
Diabetes mellitus
Men > 55 years
Women > 65 years
Family history of early onset of CVD 
  Men aged < 55 years 
  Women aged < 65 years
Waist circumference/abdominal obesity
Men ≥ 94 cm 
Women ≥ 80 cm 
The exceptions are South Asians and   
Chinese people: Men > 90 cm, and women 
> 80 cm
LVH: based on ECG 
 Sokolow-Lyons > 38 mm 
 Cornel > 2 440 mm/millisecond
Microalbuminuria: albumin/creatine ratio 
3-30 mg/mmol 
Slightly elevated creatinine 
  Men 115-133 µmol/l 




Albuminuria > 30 mg/mmol, or 
Creatinine > 133 µmol/l (men) and  
> 124 µmol/l (women)
Stroke or transient ischaemic attack
Peripheral arterial disease
Advanced retinopathy 
  Haemorrhages 
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and associated clinical conditions. The BP goal is 
< 140/90 mmHg for uncomplicated patients, and 
< 130/80 mmHg for high-risk patients. This should be 
part of an overall strategy to reduce cardiovascular risk.
Management
The diagnosis of hypertension may be made if 
repeat measurements have been performed on three 
separate occasions, and either the initial systolic BP 
(SBP) is ≥ 140 mmHg, or the diastolic BP (DBP) is 
≥ 90 mmHg, when taken over a period of two months. 
Where circumstances permit, ABPM should be considered, 
particularly in the absence of target-organ damage. If the 
SBP is ≥ 180 mmHg, or the DBP is ≥ 110 mmHg, then refer 
to the section on severe (stage III) hypertension.
Lifestyle information should be given to every person for 
whom BP is measured, but when the BP is elevated, a 
programme of lifestyle modification should be implemented 
immediately. This should include weight reduction, regular 
physical activity, cessation of smoking, moderation of 
alcohol, salt reduction, increased intake of fresh fruits and 
vegetables, and reduced fat. A healthy lifestyle decreases 
BP, enhances antihypertensive drug efficiency, and 
decreases total CV risk. 
Drug therapy
In order to use these recommendations for treatment, it 
is essential that the patient’s added CV risk is assessed 
according to Table II. The level of added CV risk informs 
the decision to implement drug therapy according to the 
decision flow chart (Figure 1.)
Drug treatment is commenced in the following cases:
•	 Low added risk where the SBP remains ≥ 140 mmHg, or 
the DBP remains ≥ 90 mmHg, despite a period of 6-12 
months of lifestyle modification and observation.
•	 Moderate added risk where the SBP remains 
≥ 140 mmHg, or the DBP remains ≥ 90 mmHg, 
despite a period of 3-6 months of lifestyle modification 
and observation.
•	 High or very high added risk.
Before choosing an antihypertensive agent, allow for 
considerations based on the cost of the various drug 
classes, patient-related factors, such as the presence 
of major risk factors, conditions favouring use and 
BEGIN DRUG
TREATMENT
High and very  
high added risk
STRATIFY ACCORDING TO ADDED RISK (as in risk chart Table II) 




Lifestyle modification as appropriate
SBP ≥ 150
or DBP ≥ 95
SBP < 150
or DBP < 95
SBP < 140
or DBP < 90
SBP ≥ 140
or DBP ≥ 90
Continue to monitor
Monitor BP and other risk factors  
for 6 – 12 months
Monitor BP and other risk factors  
for 3 – 6 months
Figure 1: Southern African hypertension management flow diagram, based on added cardiovascular disease risk
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contraindications, and associated clinical conditions 
and target-organ damage (Tables III, IV). In otherwise 
uncomplicated essential hypertension, there are three 
important antihypertensive agents, namely diuretics 
(thiazide-like and thiazide), angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin-receptor blockers 
(ARBs), and calcium-channel blockers. Therapy should 
be initiated with either a diuretic, angiotensin-converting 
enzyme (ACE) inhibitor or angiotensin-receptor blocker 
(ARB), or calcium-channel blocker. Combination 
therapy should be considered ab initio if BP is 
≥ 20/10 mmHg above goal with either an ACE inhibitor 
or ARB and diuretic; ACE inhibitor and calcium-channel 
blocker; or calcium-channel blocker and diuretic. 
In black hypertensive patients, a good combination 
would be a thiazide-like diuretic with a calcium-channel 
blocker. Fixed- drug combinations are preferred. If 
control is not achieved with monotherapy, combination 
therapy should be instituted with another drug from the 
first-line classes.
Management of severe hypertension
Patients with severe hypertension (Stage 3 DBP 
≥ 110 mmHg, or SBP ≥ 180 mmHg) may fall into one of three 
categories which determine the urgency of their treatment. 
Sustained severe hypertension requires immediate drug 
Table IV:  Indications and contraindications for the major classes of antihypertensive drugs
Class Conditions favouring the use Contraindications
Compelling Possible





Hypertensives of African origin
Gout Pregnancy
Beta blockers (especially 
atenolol)
Diuretics (loop) Renal insufficiency
Heart failure
Not used in other hypertensives Pregnancy





Calcium-channel  blockers:  
long acting only 
(dihydropyridine)
Elderly patients
























Type 1 diabetic nephropathy





Bilateral renal artery stenosis
Angioneurotic oedema (more 
common in black than in 
Caucasian individuals)
Angiotensin-receptor blockers Type 2 diabetic nephropathy
Type 2 diabetic micro- 
albuminuria
Proteinuria
Left ventricular hypertrophy ACE 
inhibitor cough or intolerance
Pregnancy
Hyperkalaemia
Bilateral renal artery stenosis
Beta blockers Angina pectoris
Post-myocardial infarction
Heart failure (some, must up-titrate)
Tachyarrhythmias
Asthma
Chronic obstructive pulmonary 
disease







Athletes and physically active 
patients
Non-dihydropyridine calcium-
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SA Hypertension Society Supplement
therapy, and lifestyle modification must be followed as soon 
as possible.
Asymptomatic severe hypertension
These patients are asymptomatic, but have severe hypertension 
with, or without, evidence of progressive target-organ damage 
or associated clinical conditions. The patient must be kept in 
the care setting and BP measurement repeated after resting 
for one hour. If the second measurement is still elevated at the 
same level, oral therapy should be started, using two drugs 
together, one of which should be a low-dose thiazide-like 
diuretic. The other is usually a dihydropyridine calcium-channel 
blocker. Follow-up should take place within a week or earlier, 
with escalation of treatment as needed. Early referral is advised 
if BP is not controlled within two to four weeks.
Hypertensive urgency 
This level of hypertension is symptomatic, usually with severe 
headache, shortness of breath and oedema. There are no 
immediate life-threatening neurological, renal, eye or cardiac 
complications, such as are seen in hypertensive emergencies. 
Ideally, all patients with hypertensive urgency should be treated 
in hospital.
Commence treatment with two oral agents, and aim to lower 
the DBP to 100 mmHg slowly, over 48-72 hours. 
This BP lowering can be achieved with the use of:
•	 Long-acting calcium-channel blockers
•	 An ACE inhibitor, initially used in very low doses, but which 
should be avoided if there is severe hyponatraemia (serum 
Na < 130 mmol/l indicates hyperreninaemia, and BP may fall 
dramatically with an ACE inhibitor).
•	 Beta blockers.
•	 Diuretics may potentiate the effects of the other classes of 
drugs when added. 
Hypertensive emergency 
A hypertensive emergency exists when acute elevation of BP 
is associated with acute and ongoing damage to the kidneys, 
brain, heart, eyes (grade 3 or 4 retinopathy), or vascular system. 
These patients need rapid (within minutes to a few hours) 
lowering of BP to safe levels. Immediate hospitalisation is 
essential, in an intensive care unit. Intravenous antihypertensive 
therapy, tailored to the specific type of emergency, has become 
the standard of care. The potential for harm from overzealous 
lowering of BP exists concurrently with the need for careful and 
structured BP reduction. 
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